Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

19.88 -2.64 (-11.72%)
Streaming Delayed Price Updated: 2:55 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Needham Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Top-Notch Biotech Apellis Soars After New Drug Obliterates Sales Views
The company easily beat sales calls on the back of Syfovre, a geography atrophy drug. 
Via Investor's Business Daily
The Latest Analyst Ratings for Apellis Pharmaceuticals
Via Benzinga
Apellis Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings Preview: Apellis Pharmaceuticals
Via Benzinga
Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Wedbush Maintains Neutral Rating for Apellis Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today
These three biotech stocks were on the volatile side today. 
Via The Motley Fool
Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma
The company is working on a treatment for the eye disease known as geographic atrophy. 
Via Investor's Business Daily
Top 5 Health Care Stocks That Could Sink Your Portfolio This Quarter
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
9 Analysts Have This to Say About Apellis Pharmaceuticals
Via Benzinga
Why Apellis Pharmaceuticals Stock Is Soaring Today
Rare disease-focused Apellis Pharmaceuticals Inc (NASDAQ: APLS) is reportedly drawing takeover interest from large drugmakers. 
Via Benzinga
Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection) for Geographic Atrophy
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Apellis Partners with Acclaimed Actor Henry Winkler to Raise Awareness of Geographic Atrophy (GA) for the GA Won’t Wait™ Campaign
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
2 Best Growth Stocks to Buy in April
Takeover interest is spurring these two biotech stocks higher. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Apellis Pharmaceuticals Inc. (NASDAQ: APLS) Making Surprising Moves in Monday Session
Via Investor Brand Network
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Apellis Pharmaceuticals, VirTra And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Wall Street Upgraded This Stock's Price Target After a New Approval: Is It a Buy?
The company's lead therapy was just approved for another indication. 
Via The Motley Fool
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.